By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Zalicus Inc. (Form 425) was posted on July 2, 2014.
The SIC code for this company is 2834, Pharmaceutical Preparations.
There was one document filed with this form. The SEC file number is 0001193125-14-259204.
The contact information for this company is 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142, 617-301-7000.
Our editors provided additional information about Form 425: Filing of certain prospectuses and communications in connection with business combination transactions.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1135906/0001193125-14-259204-index.html.
Keywords for this news article include: Pharmaceutical Preparations, SEC Filing, Zalicus Inc, Biotechnology Companies, Biopharmaceutical Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Zalicus Inc. Files SEC Form 425, Prospectuses And Communications, Business Combinations (Jul. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission
- 1 min Read
- 07.9.2014
A weekly five-point roundup of critical events in the energy transition and the implications of climate change for business and finance.
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
